Harold Burstein, MD, PhD, and other breast cancer experts at Dana-Farber discuss important breast cancer research presented at the 2025 San Antonio Breast Cancer Symposium.
I'm Doctor Harold Burstein from Dana-Farber Cancer Institute, and we're gonna be discussing some of the advances in the treatment of early and late stage breast cancer based on highlights from the San Antonio Breast Cancer symposium in December 2025 and other updates that have been presented recently. Some of the innovations we'll be focusing on include updates on antibody drug conjugates in both early and late stage disease, the developing literature on oral SEDS, other novel targeted agents entering the marketplace. The role of maintenance therapy, particularly in the management of HER2 positive advanced breast cancer, and then a couple of other very interesting discussions, a revisitation of the role of hormone replacement therapy based on newer data and considerations for breast cancer survivors, and finally a discussion of circulating tumor DNA as a prognostic and diagnostic tool for our patients. Stay with us. We're happy you're here.
